⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

AIM News

AIM ImmunoTech Inc.

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors